Related Experiment Video
Updated: Jul 4, 2026
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
[Appropriate use of anti-methicillin-resistant Staphylococcus aureus agents in a retrospective study]
Yasutaka Nakamura1, Iichirou Yokoyama, Noriko Hashimoto
1Division of Pharmacy, Chiba University Hospital, Chiba, Japan. nakay@ho.chiba-u.ac.jp
Abstract:
The track records of the use of anti-methicillin-resistant Staphylococcus aureus agents (anti-MRSA agents) in a 5-year period (2001.4-2006.3) were collected, and cases in which anti-MRSA agents were used for >4 days were selected. In each case, the results of laboratory data and bacterial examination before and after administering the anti-MRSA agents were investigated retrospectively. In addition, it was also investigated in each case whether therapeutic drug monitoring (TDM) was carried out. It was observed that the number of patients treated with anti-MRSA agents and the total dose of anti-MRSA agents used tended to increase over time, except for arbekacin sulfate. It was, however, shown that treatment with anti-MRSA agents resulted in significant decreases in body temperature, C-reactive protein, and white blood cell counts. Bacterial examination was conducted in 75.6% of the patients treated with anti-MRSA agents, with MRSA being detected in 72.4% of the cases examined. On the other hand, TDM was also conducted in 60% of the cases, but this was at a lower percentage than that of the other examinations. Quantitative bacterial examination after treatment with anti-MRSA agents indicates that TDM can be considered important for the appropriate use of anti-MRSA agents.
Insights
Anti-methicillin-resistant Staphylococcus aureus (MRSA) agent use increased, effectively reducing patient fever and inflammation. Therapeutic drug monitoring (TDM) is crucial for appropriate anti-MRSA agent use.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant clinical challenge.
- Effective treatment strategies for MRSA infections are critical.
Purpose of the Study:
- To retrospectively analyze the usage patterns and clinical outcomes of anti-MRSA agents.
- To evaluate the role of therapeutic drug monitoring (TDM) in optimizing anti-MRSA therapy.
Main Methods:
- Retrospective review of patient records using anti-MRSA agents for over 4 days between 2001 and 2006.
- Analysis of laboratory data (body temperature, C-reactive protein, white blood cell count) and bacterial examination results before and after treatment.
- Assessment of the frequency of therapeutic drug monitoring (TDM) implementation.
Main Results:
- A trend of increasing use and total dosage of anti-MRSA agents was observed, with exceptions.
- Significant reductions in body temperature, C-reactive protein, and white blood cell counts were noted post-treatment.
- MRSA was detected in 72.4% of bacterial examinations; TDM was performed in 60% of cases, less frequently than other tests.
Conclusions:
- Anti-MRSA agents demonstrate clinical efficacy in reducing key infection markers.
- Therapeutic drug monitoring (TDM) is essential for the appropriate and effective use of anti-MRSA agents.
- Further investigation into TDM protocols for MRSA treatment is warranted.
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:25Mechanism of Antibiotic Resistance in MRSA
01:29Staphylococcal Skin Infections